SCHEMBL4356262

SCHEMBL4356262

CC(C)(CCP)C(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 2/20 0.42
HRH1 P35367 2/20 0.36
SLC6A3 Q01959 2/20 0.36
CACNA1F O60840 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
ADRA2B P18089 1/20 0.36
CHRM3 P20309 1/20 0.36
ADRA1A P35348 1/20 0.36
OPRK1 P41145 1/20 0.36
CACNA1D Q01668 1/20 0.36
KCNH2 Q12809 1/20 0.36
CACNA1S Q13698 1/20 0.36
CACNA1C Q13936 1/20 0.36
SCN5A Q14524 1/20 0.36
TAAR1 Q96RJ0 3/20 0.34
HTR2A P28223 2/20 0.34
LMNA P02545 1/20 0.34
SCN4A P35499 5/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329684 0.83 RIPK1 (0.41) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL8860874 0.81 RIPK1 (0.44) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL8607432 0.79 RIPK1 (0.42) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL27450995 0.78 RIPK1 (0.41) RIPK1HTR2ALMNA
SCHEMBL9493203 0.76 LMNA (0.43) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL8634300 0.74 RIPK1 (0.44) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL8608404 0.74 RIPK1 (0.41) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL1823949 0.72 TRPA1 (0.55) RIPK1HRH1SLC6A3CACNA1FCHRM2
SCHEMBL18827501 0.72 CHRNB2 (0.52) RIPK1HRH1SLC6A3TAAR1HTR2A
SCHEMBL708842 0.70 RIPK1 (0.40) RIPK1HRH1SLC6A3CACNA1FCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618914-B2 Method for producing hydroxylamine compound using platinum catalyst fixed on ion-exchange resin WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2009-11-17 US disclosed
US-20060106254-A1 Method for producing hydroxylamine compound using platinum catalyst fixed on ion-exchange resin FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2006-05-18 US disclosed
EP-1593668-A1 METHOD FOR PRODUCING HYDROXYLAMINE COMPOUND USING PLATINUM CATALYST FIXED ON ION EXCHANGE RESIN Wako Pure Chemical Industries, Ltd. (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106254-A1 Method for producing hydroxylamine compound using platinum catalyst fixed on ion-exchange resin HNMT, HRH4, HRH3 RIPK1 1878/4885HRH1 28/4885SLC6A3 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.